We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

124 hedge funds and large institutions have $549M invested in Enanta Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 36 increasing their positions, 42 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 21

35% more capital invested

Capital invested by funds: $408M → $549M (+$141M)

12% more funds holding

Funds holding: 111 → 124 (+13)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

14% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 42

62% less call options, than puts

Call options by funds: $1.13M | Put options by funds: $2.97M

Holders
124
Holders Change
+13
Holders Change %
+11.71%
% of All Funds
3.31%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
35
Increased
36
Reduced
42
Closed
21
Calls
$1.13M
Puts
$2.97M
Net Calls
-$1.84M
Net Calls Change
-$857K

Top Buyers

1
ACM
Apex Capital Management
Ohio
+$24M
2
State Street
State Street
Massachusetts
+$17.8M
3
BFA
BlackRock Fund Advisors
California
+$11.5M
4
EAM
Eagle Asset Management
Florida
+$8.23M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.67M

Top Sellers

1
SAM
Senzar Asset Management
New York
-$23.4M
2
RCM
RA Capital Management
Massachusetts
-$9.89M
3
GC
Guggenheim Capital
Illinois
-$7.39M
4
Marshall Wace
Marshall Wace
United Kingdom
-$5.45M
5
NI
Numeric Investors
Massachusetts
-$4.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
OAM
101
Origin Asset Management
United Kingdom
$220K +$194K +4,323 New
CIBC World Market
102
CIBC World Market
Ontario, Canada
$212K +$187K +4,177 New
Truist Financial
103
Truist Financial
North Carolina
$211K -$74.4K -1,661 -29%
NI
104
Numeric Investors
Massachusetts
$203K -$4.8M -107,200 -96%
MCM
105
Manchester Capital Management
Vermont
$195K – – –
PCM
106
Prelude Capital Management
New York
$178K -$32.2K -720 -17%
SG Americas Securities
107
SG Americas Securities
New York
$111K +$97.8K +2,184 New
IMAS
108
ID Management A/S
Denmark
$102K +$40.3K +900 +82%
Legal & General Group
109
Legal & General Group
United Kingdom
$101K – – –
Simplex Trading
110
Simplex Trading
Illinois
$85K +$75.2K +1,679 New
Barclays
111
Barclays
United Kingdom
$43K -$1.68M -37,516 -98%
SGAM
112
Smith Group Asset Management
Texas
$34K – – –
Creative Planning
113
Creative Planning
Kansas
$19K -$21.5K -481 -56%
MMG
114
Monetary Management Group
Missouri
$15K +$13.4K +300 New
BlackRock
115
BlackRock
New York
$12K – – –
Teacher Retirement System of Texas
116
Teacher Retirement System of Texas
Texas
$10K -$1.61K -36 -15%
CHP
117
Cable Hill Partners
Oregon
$10K +$8.64K +193 New
SEI Investments
118
SEI Investments
Pennsylvania
$6K +$4.97K +111 New
Northwestern Mutual Wealth Management
119
Northwestern Mutual Wealth Management
Wisconsin
$5K +$4.07K +91 New
MFS
120
MSI Financial Services
Massachusetts
$4K +$3.36K +75 New
BRWA
121
B. Riley Wealth Advisors
Florida
$2.45K +$289K +6,462 New
TRCT
122
Tower Research Capital (TRC)
New York
$2K +$1.75K +39 New
Manulife (Manufacturers Life Insurance)
123
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$350 -$7.66K -171 -2%
RCM
124
RA Capital Management
Massachusetts
– -$9.89M -250,000 Closed
SCM
125
Sarissa Capital Management
Connecticut
– -$4.16M -105,000 Closed
2 3 4
5
6

ENTA Hedge Fund Activity: Q4 2014 in Review

124 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2014, worth a combined $549M — up 35% from $408M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ENTA positions and 21 closed out — a net gain of 14 holders — while 36 added to existing stakes and 42 trimmed.

The largest buyer was Apex Capital Management, adding an estimated $24M. The largest seller was Senzar Asset Management, cutting an estimated $23.4M.

  • 124 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2014, up from 111 in Q3 2014.
  • Funds reported $549M of Enanta Pharmaceuticals stock for Q4 2014, up 35% quarter-over-quarter.
  • 35 funds opened new Enanta Pharmaceuticals positions in Q4 2014 and 21 closed out, a net change of +14 holders.
  • The largest Enanta Pharmaceuticals buyer in Q4 2014 was Apex Capital Management, an estimated $24M added.
  • The largest Enanta Pharmaceuticals seller in Q4 2014 was Senzar Asset Management, an estimated $23.4M sold.

Based on aggregated 13F filings for Q4 2014.